Biological Activity of the Suppressor Cells Inducer Factor Secreted by the Jeg‐3 Choriocarcinoma Cell Line

Markert, Udo R.; Chaouat, G.

doi:10.1034/j.1600-0897.2001.d01-21.x

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The identity of the immunosuppressive factors in supernatants remains unknown so far. A 3-to 5-kd protein isolated from JEG3 choriocarcinoma cell line supernatants (56) has shown immunosuppressive effects on cellular immune response in several animal allograft models, suggesting that this protein may be useful in inducing immunosuppression associated with organ transplantation (57) .…”

Section: Soluble Inhibitory Factorsmentioning

confidence: 99%

Immunobiology of gestational trophoblastic diseases

Wang¹,

Fu²,

Freedman³

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

Gestational trophoblastic diseases (GTDs) comprise a group of interrelated diseases characterized by development after gestation, widespread metastases, and high curability with chemotherapy. The good prognosis of GTDs is considered partly a result of the host immune response to paternal antigens expressed on trophoblastic cells. In this study, we review current understanding of the immunobiology of GTDs. First of all, we describe the microenvironment between trophoblastic cells and subpopulation of immune cells. Second, immunogenetics, immune microenvironment around abnormal trophoblast, and mechanism of GTDs escaping from maternal immune system surveillance were also discussed. Third, we propose the possible immunotherapy for persistent GTDs, particularly the vaccine designed on human chorionic gonadotrophin, which is generally accepted as a tumor marker for GTDs diagnosis. Due to the low incidence of GTDs and high response to chemotherapy, there have been few literatures about immunobiologic characteristics of GTDs compared with the other gynecologic malignancies, such as ovarian cancer, but the immunologic behavior of GTDs should be explored for further understanding of the etiology of these diseases and to help designing immunotherapeutic strategies for persistent GTDs.

show abstract

Section: Soluble Inhibitory Factorsmentioning

confidence: 99%